Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Interview with Eduard Cayón
Read the interview with Eduard Cayón, Director, International Association of Pharmaceutical companies – Asociación Forum Auditorías (AFA)
- What was the biggest change leading to the revision of the Validation Process approach?
Validation of an API or pharmaceutical product manufacturing process has historically been a kind of bureaucratic exercise, consisting of three batches meeting specification, making use of standard Batch Records and using a Validation Protocol and Report (often based on a standard template).
The new approach covers the whole Product Life Cycle activity ; ongoing activity starting at development scale-up and followed until the commercial scale. Process parameters and ranges are based on Design Of Experiments (DOE).
- In your opinion, what is the main difference between the classical and modern approach?
Through this new approach, the concept of Process Validation appears as an important value for the company not only to pass inspections but also to increase knowledge, reduce incidences and at the end, enhance efficiency – adjusting efforts to actual needs.
- How can quality by design and risk management assure continual improvement under ICH Q8 and Q11? Can you give us an example?
ICH Q8 and ICH Q11 provide guidelines on how to proceed to generate and manage knowledge about the process. Risk Management is a tool to be used throughout all stages of development to optimize efforts and to ensure process robustness and safety.
When the process is developed through the Quality by Design concept, the critical operations are identified through risk analysis, and in combination with experimentation, the best ranges for the parameters are characterized. The result is a robust process leading to a fluent scale-up and industrialization. On the other hand, routine exception management will be fluent as well.
- What is your biggest expectation for the upcoming conference?
The conference’s takeaway should be basically changing the way of thinking about the validation concept. New insights show that an optimized validation approach results in benefits from the business point of view as well.
Interested in this topic?
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Targeted Drug Delivery
Gain detailed overview of the newest strategies in drug delivery and targeting.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?